Polycystic ovarian syndrome (PCOS) is a common condition that affects female fertility and is associated with other problems, including insulin resistance and cardiovascular disease. Some evidence suggests that dysregulated insulin signalling contributes to PCOS. Restuccia et al. examine this link by studying ovarian cyst formation in mice deficient for PKBβ (also known as Akt2), a kinase downstream of the insulin receptor. PKBβ-knockout mice are more susceptible to ovarian cyst formation with age, and a model of induced PCOS is more severe in PKBβ-knockout mice than in wild-type mice. Molecular analysis provides potential new treatment options for PCOS, including ERK inhibitors. These findings open up new therapeutic avenues for PCOS and caution that PKB inhibitors currently being developed to treat other indications might cause ovarian cysts as a side effect. Page 403
Polycystic ovarian syndrome: clarifying role of PKBβ
Polycystic ovarian syndrome: clarifying role of PKBβ. Dis Model Mech 1 May 2012; 5 (3): 285. doi:
Download citation file:
Advertisement
Cited by
DMM Journal Meeting 2024: Pre-clinical Modelling of Human Genetic Disease and Therapy

Registration is open for our 2024 Journal Meeting. Rapid advances in gene editing and genetic technologies have revolutionised our ability to model human genetic disease and provided new hope for gene therapies. At this Meeting, speakers will present the very latest advances in modelling human genetic disease.
Moving towards heart success – Disease Models & Mechanisms Special Issue

DMM's most recent special issue compiles articles that investigate the genetic and biological mechanisms of heart failure and identify potential therapeutic strategies.
Sustainable Conferencing Initiative

Through our Sustainable Conferencing Grants, we promote the use of new technology and greener modes of travel. Our blog posts showcase examples of sustainability in action and share guidance about how new technologies and different conference formats work in practice.
Other journals from
The Company of Biologists